Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 5 of 5 entries
View as:
Phase: N/A
Priority: Normal
Start: 03/26/20
End: 06/30/22
Due: 06/30/23
Phase: N/A
Priority: Normal
Start: 10/31/24
End: 10/31/30
Due: 10/31/31
Phase: N/A
Priority: Normal
Start: 09/30/15
End: 11/19/18
Due: 11/19/19
Phase: N/A
Priority: Normal
Start: 11/15/21
End: 01/31/25
Due: 01/31/26
Phase: N/A
Priority: Normal
Start: 08/07/23
End: 12/31/33
Due: 12/31/34
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| First in Human Feasibility Study With ADAPT 3D - ALR for Aortic Leaflet Repair | NCT04178213 | Anteris Technologies Ltd. | user2@example.com | None | 2020-03-26 | 2022-06-30 | 2023-06-30 | - | - | 2025-07-14 |
| DurAVR™ THV EU-EFS | NCT06510855 | Anteris Technologies Ltd. | user2@example.com | None | 2024-10-31 | 2030-10-31 | 2031-10-31 | - | - | 2025-07-14 |
| CardioCel Tri-leaflet Repair Study | NCT02629328 | Anteris Technologies Ltd. | user2@example.com | None | 2015-09-30 | 2018-11-19 | 2019-11-19 | - | - | 2025-07-14 |
| DurAVR™ THV System: First-In-Human Study | NCT05182307 | Anteris Technologies Ltd. | user2@example.com | None | 2021-11-15 | 2025-01-31 | 2026-01-31 | - | - | 2025-07-14 |
| Use of DurAVR™ THV System in Subjects With Severe Aortic Stenosis: Early Feasibility Study | NCT05712161 | Anteris Technologies Ltd. | user2@example.com | None | 2023-08-07 | 2033-12-31 | 2034-12-31 | - | - | 2025-07-14 |